TrialBlood2025

Safety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: the ATLAS-OLE study.

Guy Young et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.